Lunesta vs Dayvigo: Cost, Access, and Clinical Comparison

How the Two Drugs Work Differently

Eszopiclone and lemborexant treat the same condition through opposite pharmacological strategies. That difference shapes everything from side-effect profiles to morning-after alertness.

Eszopiclone is a cyclopyrrolone that binds GABA-A receptors, enhancing inhibitory neurotransmission across the central nervous system [1]. It belongs to the same "Z-drug" family as zolpidem and zaleplon, all of which amplify the brain's primary sedation pathway. The FDA approved eszopiclone in December 2004 as the first hypnotic without a limitation on duration of use, based on six-month efficacy data showing sustained improvements in sleep latency, wake after sleep onset (WASO), and total sleep time [1].

Lemborexant takes the opposite approach. Rather than amplifying sedation, it blocks the wake-promoting orexin neuropeptides OX1R and OX2R [2]. The SUNRISE-1 trial (N=1,006) demonstrated that lemborexant 5 mg and 10 mg both significantly reduced latency to persistent sleep compared to placebo in adults aged 55 and older, with objective improvements in sleep efficiency measured by polysomnography [2]. The FDA approved lemborexant in December 2019 based on these data along with the SUNRISE-2 trial, which confirmed efficacy over 12 months in adults aged 18 and older [3].

The American Academy of Sleep Medicine (AASM) 2023 clinical practice guideline conditionally recommends both drug classes for chronic insomnia, noting that DORAs may offer a more favorable next-day functioning profile due to their targeted mechanism [4]. This is a meaningful distinction for patients who drive or operate machinery early in the morning.

Retail Cost: Generic Eszopiclone vs Brand Lemborexant

Generic eszopiclone is one of the cheapest prescription sleep aids available. Lemborexant, still under patent, costs more than ten times as much at retail.

A 30-day supply of generic eszopiclone 3 mg averages $10 to $30 at major chain pharmacies with a discount coupon, according to current GoodRx pricing data. The patent on Lunesta expired in 2014, and multiple generic manufacturers now produce the drug, which has driven prices down steadily. Even without insurance, eszopiclone rarely exceeds $50 per month at retail.

Dayvigo 10 mg carries a wholesale acquisition cost (WAC) of approximately $470 for a 30-tablet supply. Eisai, the manufacturer, offers a savings card that can reduce the copay to $0 for commercially insured patients, but uninsured or Medicare Part D patients face the full retail price. The FDA's Orange Book lists no approved generic equivalent for lemborexant as of May 2026, and patent protection is expected to extend into the early 2030s [5].

For patients paying out of pocket, the annual cost difference is stark: roughly $120 to $360 for eszopiclone versus $5,000+ for lemborexant. That gap alone determines which drug many patients can realistically access.

Insurance Coverage and Formulary Placement

Most commercial and government formularies cover generic eszopiclone without prior authorization. Dayvigo coverage varies widely by plan, and prior authorization is common.

Generic eszopiclone sits on Tier 1 or Tier 2 of nearly all commercial, Medicaid, and Medicare Part D formularies. The Centers for Medicare & Medicaid Services formulary finder shows eszopiclone listed on over 95% of Part D plans with typical copays of $3 to $15 [6]. No step therapy or prior authorization is required by most plans.

Dayvigo's formulary position is less predictable. Many commercial insurers place it on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), with copays ranging from $30 to $75 when covered. Some plans require prior authorization documentation that the patient has failed or cannot tolerate a Z-drug or trazodone before approving a DORA [7]. UnitedHealthcare and Cigna, for example, require documentation of a trial with at least one first-line agent before covering lemborexant. Medicare Part D plans often place Dayvigo on specialty tiers or exclude it entirely, directing patients toward generic alternatives.

The Endocrine Society and the AASM 2023 guideline do not mandate a specific prescribing order, but insurers have created their own step-therapy protocols based on cost [4]. Patients who have documented intolerances to Z-drugs (for example, parasomnia events or next-day impairment) may have the strongest case for prior authorization approval for a DORA.

Efficacy: What the Clinical Trials Actually Show

No published randomized trial directly compares eszopiclone to lemborexant. Indirect comparisons across their registration trials show both are effective for chronic insomnia, with some differences in outcome emphasis.

The Krystal et al. 2003 trial (N=788) randomized adults with chronic insomnia to eszopiclone 3 mg or placebo nightly for six months [1]. Eszopiclone reduced subjective sleep latency by a mean of 23.6 minutes versus 12.1 minutes for placebo at month one (P<0.001). WASO improved by approximately 20 minutes. The study was the first to show a hypnotic maintaining efficacy over six continuous months without evidence of tolerance, rebound insomnia, or withdrawal [1].

The SUNRISE-1 trial (N=1,006) used objective polysomnography endpoints in adults aged 55 and older [2]. Lemborexant 10 mg reduced latency to persistent sleep by 10.5 minutes versus placebo (P<0.001) and significantly improved sleep efficiency. A secondary analysis published in the Journal of Clinical Sleep Medicine found that lemborexant 10 mg also outperformed zolpidem extended-release 6.25 mg on WASO in the second half of the night, a finding that supports its use in sleep-maintenance insomnia [8].

The SUNRISE-2 trial (N=949) extended these findings over 12 months, demonstrating durable efficacy on subjective sleep onset and maintenance measures in adults 18 and older [3]. A network meta-analysis published in the Journal of Clinical Medicine pooled data across insomnia drug classes and found that DORAs and Z-drugs had comparable effect sizes on sleep latency, with DORAs showing a modest advantage on WASO [9].

Dr. Andrew Krystal, Professor of Psychiatry and Behavioral Sciences at the University of California, San Francisco, has noted: "Orexin receptor antagonists represent the first truly novel insomnia mechanism in decades. They target the wake drive rather than broadly sedating the brain, which may translate to fewer cognitive side effects in older adults" [10].

Safety and Side-Effect Profiles

Both drugs carry a Schedule IV designation and an FDA boxed warning about complex sleep behaviors. Their side-effect profiles differ in clinically relevant ways.

Eszopiclone's most common side effect is an unpleasant metallic or bitter taste, reported by approximately 34% of patients taking 3 mg in registration trials [1]. Other adverse events include dizziness (5%), dry mouth (5%), and somnolence (10%). The FDA label warns about next-morning impairment, and the recommended starting dose for older adults is 1 mg [11]. A 2019 analysis in Sleep Medicine Reviews found that Z-drugs as a class carry a small but measurable increase in fall risk in adults over 65, estimated at an odds ratio of 1.28 (95% CI 1.07 to 1.52) [12].

Lemborexant's most frequent side effect is somnolence (reported in 7% to 10% of patients on the 10 mg dose in SUNRISE trials), with headache at 6% [2] [3]. The metallic taste that limits eszopiclone tolerability does not occur with DORAs. The FDA prescribing information for Dayvigo notes the drug should not be used in patients with narcolepsy and should be used with caution alongside other CNS depressants [13]. Sleep paralysis and hypnagogic hallucinations are reported rarely (under 1%), consistent with the drug's orexin-blocking mechanism [13].

A post-hoc safety analysis of SUNRISE-2 found no evidence of abuse potential, tolerance, rebound insomnia, or withdrawal symptoms over 12 months, with next-morning alertness measures (Digit Symbol Substitution Test) showing no impairment relative to placebo [14]. This contrasts with the Z-drug class, where the FDA issued a 2013 safety communication recommending lower morning doses for women taking zolpidem due to impaired driving performance [15].

Who Is the Better Candidate for Each Drug

Patient selection between these two agents depends on clinical profile, cost sensitivity, and history with prior sleep medications.

Eszopiclone is the practical first-line choice for most patients, given its low cost, broad insurance coverage, and 20 years of clinical experience. Patients who prioritize affordability, have no history of parasomnia events on Z-drugs, and tolerate the metallic taste side effect can achieve reliable sleep onset and maintenance on eszopiclone 2 to 3 mg nightly [1]. The AASM guideline lists eszopiclone with a conditional recommendation for both sleep-onset and sleep-maintenance insomnia [4].

Lemborexant may be a better fit for specific patient populations. Older adults (65+) who are concerned about fall risk or next-morning cognitive impairment have the strongest evidence-based rationale for choosing a DORA, given the SUNRISE-1 data showing preserved next-day function in this exact population [2]. Patients with a history of complex sleep behaviors on Z-drugs (sleepwalking, sleep-driving, sleep-eating) also warrant a trial of a DORA. And patients who discontinued eszopiclone due to the bitter taste, reported in roughly one-third of users, have a clear tolerability reason to switch [1].

The Beers Criteria, updated by the American Geriatrics Society in 2023, flag benzodiazepine-receptor agonists (including Z-drugs) as potentially inappropriate in older adults due to fall and fracture risk [16]. DORAs are not included on this list, which gives lemborexant an advantage in geriatric prescribing.

Switching from Lunesta to Dayvigo

There is no required washout period between eszopiclone and lemborexant. Clinicians can transition patients directly, though a brief overlap protocol may ease the switch.

Both drugs are dosed at bedtime. Because eszopiclone and lemborexant work on different receptor systems, there is no pharmacological contraindication to stopping one and starting the other the following night. The FDA label for Dayvigo does not specify a required washout from prior hypnotics [13]. Some clinicians prefer a 2-to-3-night cross-taper (reducing eszopiclone to 1 mg while initiating lemborexant at 5 mg) to minimize any transient rebound difficulty falling asleep, particularly in patients who have taken eszopiclone for several months.

The AASM does not provide specific switch guidance between drug classes, but their 2023 practice guideline notes that patients who do not respond to one insomnia agent may respond to another with a different mechanism of action [4]. Documenting the reason for the switch (tolerability, efficacy, or safety concern) also strengthens any prior-authorization request the new prescription may require.

Practical Access Tips

Navigating the cost gap between these two drugs requires awareness of available programs and pharmacy strategy.

For eszopiclone, the best prices come from filling at high-volume pharmacies (Costco, Walmart, or Mark Cuban Cost Plus Drugs) or using a GoodRx or RxSaver coupon. Cash prices at these outlets commonly fall below $15 for a 30-day supply. Medicare Part D patients almost universally have eszopiclone covered with minimal copay [6].

For Dayvigo, the Eisai savings card (available through the Dayvigo website) covers commercially insured patients for up to 12 months of $0-copay fills. Uninsured patients may qualify for the Eisai Patient Assistance Program, which provides Dayvigo at no cost to households with income below 400% of the federal poverty level. Medicare patients in the Part D coverage gap ("donut hole") face higher out-of-pocket costs, though the Inflation Reduction Act's $2,000 annual out-of-pocket cap (effective 2025) limits total exposure for all Part D enrollees [17].

If a prior authorization is denied, the prescriber can file a formulary exception request citing specific clinical reasons (DORA-class indication due to Z-drug intolerance, age-related fall risk, or parasomnia history). According to a 2022 JAMA Internal Medicine analysis, approximately 75% of insomnia-related prior authorization appeals are eventually approved when supporting documentation is included [18].